Psoriasis Drug Market is expected to reach $59.85 billion by 2032, growing at a CAGR of 9.2%

The global psoriasis drug market size is expected to reach USD 59.85 billion by 2032, expected to grow at a CAGR of 9.2% during the forecast period.

The Psoriasis Drug Market is a rapidly evolving segment within the global dermatology market. Psoriasis is a chronic, autoimmune skin disorder that leads to the rapid growth of skin cells, forming scales and red patches that can be itchy, painful, and unsightly. It affects millions of people worldwide, and its severity can range from mild to severe. As a result, there is a significant demand for effective treatments to manage the symptoms, reduce flare-ups, and improve the quality of life for patients.

Market Growth Drivers

1. Increasing Prevalence of Psoriasis
   • Psoriasis affects millions of people worldwide, with estimates suggesting that approximately 2–3% of the global population suffers from the condition. The increasing prevalence, especially in developed countries, is driving demand for effective treatments.
2. Advancements in Biologic Therapies
   • Biologic drugs have revolutionized the treatment of psoriasis by targeting specific immune system pathways involved in the disease. These drugs, including TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors, offer better efficacy and fewer side effects than traditional systemic therapies, driving market growth.
3. Rising Awareness and Diagnosis
   • Growing awareness among both patients and healthcare providers about psoriasis and available treatments is leading to earlier diagnosis and treatment initiation. This is increasing the demand for psoriasis drugs.

Some of the major players operating in the global market include:

• Amgen Inc.
• AbbVie Inc.
• Johnson & Johnson Inc.
• Novartis AG
• Eli Lily and Company
• AstraZeneca plc
• Celgene Corporation
• Sun Pharma
• Boehringer Ingelheim
• Evelo Biosciences Inc.
• LEO Pharma A/S
• Pfizer Inc
• UCB S.A
• Sun Pharmaceutical Industries Ltd

Download Free Sample PDF Copy of the Report:

https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market/request-for-sample

Key Trends in the Psoriasis Drug Market

1. Shift Toward Biologic Drugs
   • The psoriasis drug market has seen a significant shift toward biologic therapies, which are considered the gold standard for moderate-to-severe cases of psoriasis. These drugs, including biologics like Humira (adalimumab), Enbrel (etanercept), and Cosentyx (secukinumab), work by targeting specific molecules in the immune system that contribute to the inflammation and skin cell turnover seen in psoriasis.
2. Increasing Focus on Personalized Medicine
   • Personalized medicine, which tailors treatment based on a patient’s genetic makeup, is gaining momentum in psoriasis treatment. Understanding the molecular and genetic factors contributing to psoriasis can help identify which treatments will be most effective for individual patients, improving outcomes.
3. Oral Therapies Gaining Popularity
   • Oral treatments like Otezla (apremilast), a phosphodiesterase 4 (PDE4) inhibitor, are gaining popularity due to their ease of use compared to injections. Oral therapies provide a less invasive treatment option for patients, particularly for those who are hesitant to use injectable biologics.

Recent Developments

• In July 2022, Arcutis Biotherapeutics, Inc got approval from U.S. Food and Drug Administration for New Drug Application for the topical creme ZORYVE (roflumilast) 0.3% to treat plaque psoriasis in 12 years of patient or older.
• In May 2022, Dermavant Sciences received approval for VTAMA (tapinarof) 1% cream, an aryl receptor agonist, from U.S. FDA for treating plaque psoriasis in adult patients. It’s the first steroid-free topical medication.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.

Psoriasis Drug, Therapeutic Class Outlook (Revenue – USD Billion, 2019 – 2032)

• Interleukin Inhibitors
• Tumour Necrosis Factor Inhibitor
• Vitamin D Analogues

Psoriasis Drug, Type Outlook (Revenue – USD Billion, 2019 – 2032)

• Psoriatic Arthritis
• Plaque Psoriasis
• Others

Psoriasis Drug, Treatment Type Outlook (Revenue – USD Billion, 2019 – 2032)

• Topical
• Systematic
• Biologics

The Psoriasis Drug Market is set for continued growth driven by advances in biologic therapies, oral medications, and personalized treatment approaches. As the global prevalence of psoriasis rises and treatment options continue to evolve, there is increasing demand for effective therapies that can improve patient outcomes and quality of life. Despite challenges like high treatment costs and side effects, the market remains dynamic, with significant investments in research and development to bring innovative therapies to market. The adoption of targeted treatments, biologics, and JAK inhibitors will continue to shape the future of psoriasis management.